Early Observations: Comparing FDA Inspection Outcomes

Striking Difference in Inspection Outcomes for Domestic and Foreign Device Manufacturers

One of the most revealing early insights from our analysis of FDA inspection data emerges when the results are separated between U.S. and foreign medical device manufacturers. The difference is more striking than expected.

Our dataset includes 24,152 device inspections conducted between 2016 and early 2026, consisting of 19,805 inspections of U.S. manufacturers and 4,347 inspections of non-U.S. manufacturers.

While foreign inspections represent a much smaller share of total inspection activity, their outcomes differ significantly from those of domestic manufacturers.

Overall Inspection Outcomes

For U.S. device manufacturers, inspection outcomes across the dataset were:

No Action Indicated (NAI): 61.8%

Voluntary Action Indicated (VAI): 35.2%

Official Action Indicated (OAI): 3.0%

For foreign manufacturers, the distribution shifts noticeably:

NAI: 48.8%

VAI: 43.0%

OAI: 8.2%

In practical terms, this means foreign manufacturers in this dataset were significantly less likely to receive NAI classifications, more likely to receive VAI findings, and nearly three times as likely to receive OAI outcomes.

That gap is large enough to warrant closer examination.

Patterns Over Time

Looking at inspection outcomes year by year from 2016 to 2026 reveals another important distinction. Inspection outcomes for U.S. manufacturers are relatively stable across the decade. NAI outcomes typically fall between 59% and 65%, while OAI outcomes generally remain between 2.5% and 3.8%.

Foreign inspections show a much more volatile pattern, particularly in the years following the COVID-era pause in international inspections.

Notable OAI rates for foreign inspections include:

2019: 7.3%

2020: 14.5%

2022: 15.0%

2023: 14.9%

2024: 9.6%

2025: 8.1%

Even allowing for smaller sample sizes in foreign inspections, these differences appear substantial.

What Could Explain the Gap?

At this stage, the data supports a clear observation that foreign medical device manufacturers appear to face a materially higher risk of adverse FDA inspection outcomes than U.S. manufacturers. However, the data alone cannot fully explain why.

Several possible factors may contribute. FDA may prioritize inspections of higher-risk foreign facilities, foreign manufacturers may face greater challenges implementing FDA-specific regulatory expectations, there may be differences in quality system maturity or documentation practices, and the complexity of global supply chains and outsourced manufacturing.

Determining which of these factors is most influential requires deeper examination of the inspection findings themselves.

Why the 483 Observations Matter

Inspection outcome classifications (NAI, VAI, OAI) tell us how serious the inspection findings were, but they do not reveal the underlying causes of those findings.

That information is contained in Form FDA-483 inspection observations, where investigators document specific regulatory deficiencies.

Reviewing the 483 reports will allow us to explore questions such as

Are foreign OAI outcomes driven primarily by CAPA system failures?

Do they involve documentation and recordkeeping deficiencies?

Are complaint handling or MDR procedures more frequently cited?

Do foreign manufacturers show more process validation or supplier control issues?

These details can help explain the mechanisms behind the outcome gap observed in the inspection data.

Next Steps in the Analysis

The inspection outcome data provide a valuable starting point, but they only represent the first layer of insight.

The next phase of this research will focus on reviewing a structured sample of Form FDA-483 inspection reports, with particular attention to foreign inspections with OAI and VAI findings, a comparison sample of U.S. OAI inspections, and any inspections referencing ISO 13485 requirements.

By examining the actual observations documented during inspections, we can begin to understand what types of quality system failures are driving the differences in inspection outcomes.

The results of that analysis will provide a clearer picture of how medical device quality systems perform under FDA oversight, and what manufacturers can learn from the collective experience of thousands of inspections.

Pharmacal Recalls MG217 Eczema Cream

Pharmacal Recalls MG217 Eczema Cream Due to Staphylococcus aureus ContaminationFDA posts nationwide recall after microbial contamination found in topical skin treatment Pharmacal has voluntarily recalled one lot of MG217 Multi-Symptom Treatment Cream & Skin...

First T-Cell Therapy to Reduce Disease after Cell Transplant

FDA Approves First Regulatory T-Cell Therapy to Reduce Chronic Graft-versus-Host Disease After Stem Cell TransplantThe First Regulatory T (Treg) Cell-Based Immunotherapy The U.S. Food and Drug Administration (FDA) has approved Tregzi, the first regulatory T (Treg)...

Moringa Capsules Recalled for Potential Salmonella Contamination

Zen Principle Recalls Moringa Capsules After FDA Detects Salmonella in Raw Ingredient Relay Peak Research LLC, doing business as Zen Principle Naturals, has voluntarily recalled one lot of its Zen Principle® Moringa Capsules after learning that the raw moringa leaf...

Eight Months of Moringa Salmonella Outbreaks

Recurring Salmonella Outbreaks Raise Questions About Supplement Oversight Since November 2025, the U.S. Food and Drug Administration has investigated and coordinated multiple recalls involving moringa dietary supplements contaminated with Salmonella. What initially...